Global regional differences seen in patient characteristics, treatment, and outcomes
By Lori Solomon HealthDay Reporter
THURSDAY, July 18, 2024 (HealthDay News) — There is substantial geographic variation in patient characteristics, treatment, and outcomes among patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), according to a study published online June 23 in the European Journal of Heart Failure.
Mingming Yang, from the University of Glasgow in the United Kingdom, and colleagues investigated geographic differences in HFpEF and HFmrEF across five global regions. The analysis included 19,959 patients (23.1 percent with HFmrEF).
The researchers found that regardless of HF phenotype, patients from Western Europe were oldest and those in Central/Eastern Europe and Russia were youngest. Latin America had the greatest portion of females, while North America had the most Black patients. In North America, obesity and diabetes were most prevalent, while hypertension and coronary heart disease most common in Central/Eastern Europe and Russia. Self-reported health status varied widely and was the worst in North America and best in Asia-Pacific. Rates of the primary composite end point (cardiovascular death or HF hospitalization) among patients with HFmrEF were 12.56 per 100 patient-years in North America, 11.67 in Asia-Pacific, 10.12 in Central/Eastern Europe and Russia, 8.90 in Latin America, and 8.43 in Western Europe. For HFpEF, the corresponding rates were 11.47, 7.80, 5.47, 5.92, and 7.80. The primary composite end point was driven by differences in the rate of HF hospitalization.
“These findings have implications for interpretation and generalizability of trial results, design and conduct of future trials, and optimization of care for these patients,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
